Presence of Non-classic LCIS Is Not a Contraindication to Breast Conservation in Patients with Concomitant Invasive Breast Cancer or DCIS

[1]  T. King,et al.  Comparison of Outcomes for Classic-Type Lobular Carcinoma In Situ Managed with Surgical Excision After Core Biopsy Versus Observation , 2021, Annals of Surgical Oncology.

[2]  S. Schnitt,et al.  Atypical Lobular Hyperplasia and Classic Lobular Carcinoma In Situ Can Be Safely Managed Without Surgical Excision , 2021, Annals of Surgical Oncology.

[3]  E. Brogi,et al.  Morphologic subtypes of lobular carcinoma in situ diagnosed on core needle biopsy: clinicopathologic features and findings at follow-up excision , 2021, Modern Pathology.

[4]  G. Eslick,et al.  Impact of lobular carcinoma in situ on local recurrence in breast cancer treated with breast conservation therapy: a systematic review and meta‐analysis , 2021, ANZ journal of surgery.

[5]  J. Margenthaler,et al.  The Landmark Series: Breast Conservation Trials (including oncoplastic breast surgery) , 2021, Annals of Surgical Oncology.

[6]  S. Lakhani,et al.  American registry of pathology expert opinions: The spectrum of lobular carcinoma in situ: Diagnostic features and clinical implications. , 2020, Annals of diagnostic pathology.

[7]  S. Schnitt,et al.  Genomic profiling of pleomorphic and florid lobular carcinoma in situ reveals highly recurrent ERBB2 and ERRB3 alterations , 2020, Modern Pathology.

[8]  S. Hajiyeva,et al.  Outcomes of classic lobular neoplasia diagnosed on breast core needle biopsy: a retrospective multi-center study , 2019, Virchows Archiv.

[9]  E. Zabor,et al.  Risk of Contralateral Breast Cancer in Women with Ductal Carcinoma In Situ Associated with Synchronous Ipsilateral Lobular Carcinoma In Situ , 2019, Annals of Surgical Oncology.

[10]  P. Querzoli,et al.  Pre-operative management of Pleomorphic and florid lobular carcinoma in situ of the breast: Report of a large multi-institutional series and review of the literature. , 2019, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[11]  S. Coopey,et al.  Evaluating the Rate of Upgrade to Invasive Breast Cancer and/or Ductal Carcinoma In Situ Following a Core Biopsy Diagnosis of Non-classic Lobular Carcinoma In Situ , 2018, Annals of Surgical Oncology.

[12]  W. Barry,et al.  Population-Based Analysis of Breast Cancer Incidence and Survival Outcomes in Women Diagnosed with Lobular Carcinoma In Situ , 2017, Annals of Surgical Oncology.

[13]  C. Hudis,et al.  Incidence of Adjacent Synchronous Invasive Carcinoma and/or Ductal Carcinoma In-situ in Patients with Lobular Neoplasia on Core Biopsy: Results from a Prospective Multi-Institutional Registry (TBCRC 020) , 2016, Annals of Surgical Oncology.

[14]  J. Reis-Filho,et al.  Lobular Carcinoma in Situ: A 29-Year Longitudinal Experience Evaluating Clinicopathologic Features and Breast Cancer Risk. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  M. Rendi,et al.  Pleomorphic Lobular Carcinoma In Situ: Radiologic–Pathologic Features and Clinical Management , 2015, Annals of Surgical Oncology.

[16]  F. Ong,et al.  Pattern of ipsilateral breast tumor recurrence after breast-conserving therapy. , 2014, International Journal of Radiation Oncology, Biology, Physics.

[17]  H. Gobbi,et al.  Inter-observer variability between general pathologists and a specialist in breast pathology in the diagnosis of lobular neoplasia, columnar cell lesions, atypical ductal hyperplasia and ductal carcinoma in situ of the breast , 2014, Diagnostic Pathology.

[18]  Seema A. Khan,et al.  Society of Surgical Oncology–American Society for Radiation Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Stages I and II Invasive Breast Cancer , 2014, Annals of Surgical Oncology.

[19]  Tari A King,et al.  Lobular neoplasia. , 2014, Surgical oncology clinics of North America.

[20]  A. Niemierko,et al.  Risk of local failure in breast cancer patients with lobular carcinoma in situ at the final surgical margins: is re-excision necessary? , 2013, International journal of radiation oncology, biology, physics.

[21]  Charles G Luedtke,et al.  Classic lobular carcinoma in situ and atypical lobular hyperplasia at percutaneous breast core biopsy , 2013, Cancer.

[22]  E. Hwang,et al.  Breast Surgeon's Survey: No Consensus for Surgical Treatment of Pleomorphic Lobular Carcinoma In Situ , 2013, The breast journal.

[23]  T. Julian,et al.  Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. , 2011, Journal of the National Cancer Institute.

[24]  B. Susnik,et al.  Lobular carcinoma in situ variants in breast cores: potential for misdiagnosis, upgrade rates at surgical excision, and practical implications. , 2010, Archives of pathology & laboratory medicine.

[25]  D. Oertli,et al.  Factors predicting in-breast tumor recurrence after breast-conserving surgery , 2009, Breast Cancer Research and Treatment.

[26]  N. Afonso,et al.  Lobular carcinoma in situ , 2008, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[27]  M. Morrow,et al.  Presence of Lobular Carcinoma In Situ Does Not Increase Local Recurrence in Patients Treated with Breast-Conserving Therapy , 2008, Annals of Surgical Oncology.

[28]  H. Mouridsen,et al.  Long-term results of breast conserving surgery vs. mastectomy for early stage invasive breast cancer: 20-year follow-up of the Danish randomized DBCG-82TM protocol , 2008, Acta oncologica.

[29]  S. Jolly,et al.  The impact of lobular carcinoma in situ in association with invasive breast cancer on the rate of local recurrence in patients with early-stage breast cancer treated with breast-conserving therapy. , 2006, International journal of radiation oncology, biology, physics.

[30]  K. Griffith,et al.  Is lobular carcinoma in situ as a component of breast carcinoma a risk factor for local failure after breast‐conserving therapy? , 2006, Cancer.

[31]  Norman Wolmark,et al.  Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project , 2004, Cancer.

[32]  B. E. F. Isher,et al.  Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. , 2002 .

[33]  A. Patchefsky,et al.  Lobular carcinoma in situ increases the risk of local recurrence in selected patients with stages I and II breast carcinoma treated with conservative surgery and radiation , 2001 .

[34]  E van der Schueren,et al.  Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial. , 2001, Journal of the National Cancer Institute.

[35]  Richard Sylvester,et al.  Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial. , 2000, Journal of the National Cancer Institute.

[36]  S. Schnitt,et al.  The relation between the presence and extent of lobular carcinoma in situ and the risk of local recurrence for patients with infiltrating carcinoma of the breast treated with conservative surgery and radiation therapy , 2000, Cancer.

[37]  B. Haffty,et al.  Lobular carcinoma in situ as a component of breast cancer: the long-term outcome in patients treated with breast-conservation therapy. , 1998, International journal of radiation oncology, biology, physics.

[38]  F. W. Foote,et al.  Classics in oncology: Lobular carcinoma in situ: A rare form of mammary cancer , 1982 .